Trocoxil

For the treatment of pain and inflammation associated with degenerative joint disease in dogs.

TROCOXIL^® Chewable Tablets for Dogs contain mavacoxib, a non-steroidal, anti-inflammatory drug (NSAID), with analgesic and anti-inflammatory properties. Mavacoxib is an inhibitor of cyclo-oxygenase (COX), and is preferential for COX-2. Mavacoxib is slowly eliminated from the body resulting in its prolonged anti-inflammatory effect, which allows for monthly dosing (after initial 2 week jump-start dose).

FAST & EFFECTIVE

• Reaches theraputic levels within one hour of administration¹
• Very good efficacy², equivilant to carprofen (4mg/kg)

LONG-ACTING

• A dose of 2mg/kg maintains therapeutic levels for the entire month^3-7
• The duration allows for improved compliance, resulting in an improved medication regime. This consistent treatment can prevent/treat the consequences of long-term inflammation, including central sensitisation

WIDE SAFETY MARGIN

• Well tolerated at 7.5x reommended dose for 6.5 months
• At 5x the recommended dose. TROCOXIL ahowed no abnormalities on gastric endoscopy or buccal mucosal bleeding times

TROCOXIL^® Chewable Tablets for Dogs are triangular, mottled brown appearance containing either 20mg, 30mg, 75mg or 95mg of mavacoxib. Presented in blister packs containing two tablets.

For oral use only. A dose of 2mg/kg is given monthly (after initial 2 week jump-start dose). A treatment cycle with TROCOXIL should not exceed 7 consecutive doses (6.5 months). Dosage must be administered with a full meal (to enhance uptake of active). Care must be taken to keep tablets away from children or other animals.

Please click here for further dosage information (include link to dosage chart)

Should be used with caution in dogs that have already shown sensitivity to non-steroidal, anti-inflammatory drugs. Use in conjunction with other NSAIDs or steroids should be avoided.

Mavacoxib has been administered to dogs at 7.5x recommended dose for 6.5 months with no clinically significant adverse events. The ulcerogenic dose in dogs was found to be 25mg/kg orally.

Mavacoxib is an NSAID, and, as with others in the class, adverse reactions may occur with its use. Typical adverse reactions of NSAIDs include loss of appetite, vomiting, diarrhoea, melaena or faecal occult blood, and lethargy. In most cases, side effects are transient. Owners should be advised not to give any further tablets and contact their veterinary surgeon immediately if signs of intolerance are observed.

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal and renal toxicity. Effects may result from decreased prostaglandin production and inhibition of the enzyme cyclo-oxygenase, which is responsible for the formation of prostaglandins from arachidonic acid. When NSAIDs inhibit prostaglandins that cause inflammation they may also inhibit those prostaglandins that maintain homeostatic function. These anti-prostaglandin effects may result in clinically significant effects in animals with underlying or pre-existing disease more often than in healthy animals. Sensitivity to drug-associated adverse effects varies with the individual animal.

All dogs should undergo a thorough clinical examination and appropriate laboratory tests before introduction of NSAID therapy. Appropriate laboratory tests and periodic re-examination during extended administration should be considered. NSAID therapy could unmask occult disease, which has previously been undiagnosed due to the absence of clinical signs. Therefore, use with caution in animals that are debilitated and aged or with existing cardiac, hepatic or renal disease or are dehydrated, hypovolaemic or hypotensive. Use with caution in dogs with bleeding disorders (eg. von Willebrand's disease), as safety has not been established in dogs with these disorders. The safe use in pregnant and lactating bitches and dogs used for breeding purposes has not been established. If changing anti-inflammatory products, take into account the pharmacokinetic properties of the drugs used previously when considering the time to allow before starting the new treatment. Due to the palatable nature of the tablets, owners should be advised to store out of reach of dogs in a secured location. Access to tablets may lead to ingestion of large quantities with resultant toxicity. Dispense only in a child-resistant safety dispensing container.

Store below 30°C (room temperature).

DO NOT USE in cats or food producing animals.

Zoetis Animal Health New Zealand Limited. Level 5, 8 Mahuhu Crescent, Auckland 1010, New Zealand. Tel: 0800 650 277, Fax: 0800 628 629. TROCOXIL is a registered trade mark of Zoetis Inc. or its subsidiaries. ACVM Registration No. A10459. RVM; Available only under Veterinary Authorisation.

References:

1. Zoetis Study Number 1560N-60-05-697. 70-day dose proportionality study of mavacoxib (PHA- 739521) in dogs.
2. Payne-Johnson M. Et al. Efficacy and Safety of Mavacoxib in the Treatment of Pain and Inflammation Associated with Degenerative Joint Disease in Dogs Presented as Veterinary Patients. EAVPT 2009 Proceedings.
3. Zoetis study number 1D61C-60-04-677. Dose response of PHA-739521 oral tablets compared to a negative control in an induced-lameness canine acute synovitis model 30 days following completion of a loading dose interval
4. Zoetis study number 2001-pmg-03. Evaluation of SC-58500 at 2 mg/kg PO in a canine inflammation model: comparison of efficacy and plasma concentrations.
5. Zoetis study number 2002-pmg-03. Evaluation of SC-58500 at 4 mg/kg in a canine inflammation model
6. Zoetis study number 7961W-60-03-409. Analgesic efficacy of PHA-739,521 in the canine synovitis model.
7. Zoetis study number 0851-8625-O-PBM-2001-001. Evaluation of the efficacy of a novel nonsteroidal anti-inflammatory drug (NSAID) for the treatment of osteoarthrosis in vivo.

For technical enquiries please phone Zoetis Technical Services on 0800 650 277.

• Zoetis Safety Data Sheets
• TROCOXIL Dosing Chart
• Label: http://www.foodsafety.govt.nz/

Dogs
Antibiotics, parasite control, pain management and disease prevention for dogs.